What is the future of bromodomains in targeted drug development? Read more about What is the future of bromodomains in targeted drug development?
Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. Read more about Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching.
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. Read more about Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Recently targeted kinases and their inhibitors-the path to clinical trials. Read more about Recently targeted kinases and their inhibitors-the path to clinical trials.
Lost but making progress-Where will new analgesic drugs come from? Read more about Lost but making progress-Where will new analgesic drugs come from?
Functional Characterization and Categorization of Missense Mutations that Cause Methylmalonyl-CoA Mutase (MUT) Deficiency. Read more about Functional Characterization and Categorization of Missense Mutations that Cause Methylmalonyl-CoA Mutase (MUT) Deficiency.
ACVR1 Mutations in DIPG: Lessons Learned from FOP. Read more about ACVR1 Mutations in DIPG: Lessons Learned from FOP.
(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Read more about (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.
The Crystal Structure of the RhoA : AKAP-Lbc DH-PH Domain Complex. Read more about The Crystal Structure of the RhoA : AKAP-Lbc DH-PH Domain Complex.
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Read more about A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.
